Skip to main content
Premium Trial:

Request an Annual Quote

Guava Technologies

Premium
Guava Technologies has launched its Guava Nexin assay, the company announced this week.  
 
The newly revised assay, for the first time, provides all necessary reagent components in a single cocktail, the company said. The newly reformulated Guava Nexin reagent eliminates the need for pre-assay dilutions, cocktail preparations, or time consuming wash steps. The assay protocol is identical for use on all Guava systems, using both tube- and plate-based approaches. 
 
The new mix-and-read Guava Nexin assay relies on a two-dye strategy. The assay uses Annexin V-PE to detect the translocation of phosphatidylserine to the external surface of the membrane of apoptotic cells. The assay incorporates this PS-Annexin V-PE binding as an indicator of early-stage apoptotic cells. The cell impermeant dye 7-AAD is included in the Guava Nexin reagent as an indicator of membrane structural integrity.
 
7-AAD is excluded from live healthy cells and early apoptotic cells, but permeates late stage apoptotic and dead cells. In conjunction, the two dyes, added in one step as a reagent cocktail, provide quick and accurate determination of early- and late-stage cellular apoptosis, the company said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.